Picture loading failed.

Anti-CSF1 therapeutic antibody (Pre-made Lacnotuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lacnotuzumab, as known as MCS110, is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1 from activating the CSF-1R. The drug is being developed by Novartis Europharm Limited.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-289-1mg 1mg 3090
GMP-Bios-ab-289-10mg 10mg 21890
GMP-Bios-ab-289-100mg 100mg 148000
GMP-Bios-ab-289-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CSF1 therapeutic antibody (Pre-made Lacnotuzumab biosimilar,Whole mAb)
INN Name Lacnotuzumab
TargetCSF1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesDana-Farber Cancer Institute;Novartis;Novartis Oncology;Seoul National University Hospital
Conditions Approvedna
Conditions ActiveBreast cancer;Gastric cancer;Giant cell tumour of tendon sheath;Pigmented villonodular synovitis;Malignant melanoma;Solid tumours
Conditions DiscontinuedBone metastases;Prostate cancer
Development Techna